Indole 3-acetate and response to therapy in pancreatic cancer
Author Information
Author(s): Braadland Peder R., Farnes Ingvild, Kure Elin H., Yaqub Sheraz, McCann Adrian, Ueland Per M., Labori Knut Jørgen, Hov Johannes R.
Primary Institution: Oslo University Hospital
Hypothesis
Does elevated serum indole 3-acetate (3-IAA) associate with therapeutic response in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma (PDAC)?
Conclusion
High levels of 3-IAA do not predict chemotherapy response in patients with borderline resectable or locally advanced PDAC.
Supporting Evidence
- The median serum 3-IAA concentration before chemotherapy was 290 ng/mL.
- Pre-treatment 3-IAA was similar across different chemotherapy groups.
- The study included a larger cohort than previous studies but focused on non-metastatic patients.
Takeaway
The study looked at a substance called 3-IAA in patients with pancreatic cancer to see if it helps them respond better to treatment, but it turns out it doesn't really help.
Methodology
Measured circulating 3-IAA in blood samples from 124 patients before chemotherapy and analyzed the association with overall survival using Cox proportional hazards regression.
Limitations
The study had a high percentage of patients with biliary stents, and only a subset had follow-up blood samples taken.
Participant Demographics
Median age 68 years, 47% male.
Statistical Information
P-Value
p=0.52
Confidence Interval
95% CI [0.74–1.16]
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website